VistaGen Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for VTGN, updated each market day.
VTGN AI Sentiment
AI predicts VistaGen Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: July 1, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About VistaGen Therapeutics, Inc. Common Stock
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Sector
Exchange
Market Cap
$25,300,610
Cap Tier
Employees
41
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
July 1, 2009
Website
VTGN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VTGN Volatility
VistaGen Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
